ArticleFrontiers in immunology2026
Neuroimmune activation of the TRPV1-RAMP1 axis drives type 2 immunity to repair intestinal barrier and alleviate metabolic disease.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Obesity is closely associated with intestinal barrier dysfunction and chronic inflammation. Group 2 innate lymphoid cells (ILC2s) can receive and integrate signals from neuropeptides, neurotransmitters, and epithelial cells, thereby regulating local tissue inflammatory responses and promoting repair. However, the specific mechanism by which the nociceptor Transient Receptor Potential Vanilloid 1 (TRPV1) interacts with ILC2s to regulate intestinal homeostasis in obesity remains unclear. Objective: This study aimed to investigate whether electroacupuncture (EA) ameliorated obesity-mediated intestinal injury by modulating type 2 immune responses via the TRPV1- calcitonin gene-related peptide (CGRP)- receptor activity-modifying protein 1 (RAMP1) axis. Methods: A high-fat diet-induced obese mouse model was employed. The expression levels of TRPV1 and CGRP, the abundance of ILC2s, and the levels of type 2 cytokines IL-5 and IL-13 in colon tissues were assessed using flow cytometry, immunofluorescence staining, and Western blotting. Intestinal pathological changes and goblet cell status were evaluated via hematoxylin and eosin staining and Alcian blue-periodic acid-Schiff staining. Mechanistic verification was performed by specific ablation of TRPV1 Results: EA treatment significantly increased CGRP derived from TRPV1-expressing sensory neurons, which subsequently activated type 2 immunity, as evidenced by the expansion of ILC2s and upregulation of related cytokines. This immune activation ultimately promoted the differentiation and proliferation of goblet cells and ameliorated high-fat diet-induced intestinal barrier damage. Notably, in mice with specific ablation of TRPV1 Conclusion: Our findings demonstrate that electroacupuncture activates intestinal type 2 immunity via the TRPV1-CGRP-RAMP1 axis, identifying this pathway as a crucial mechanism for repairing obesity-associated intestinal barrier dysfunction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.